Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.57 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7430034 | 0.93 | DRD2 (0.51) | DRD2DRD3SIGMAR1SMN1; SMN2HTR6 | |
| SCHEMBL2926804 | 0.93 | DRD2 (0.51) | DRD2DRD3SMN1; SMN2 | |
| SCHEMBL2928909 | 0.90 | KDM2B (0.48) | DRD2DRD3SMN1; SMN2HTR6POLB | |
| SCHEMBL2922399 | 0.82 | TMEM97 (0.45) | SIGMAR1SMN1; SMN2POLBMAPK1LMNA | |
| SCHEMBL2928035 | 0.82 | DRD2 (0.60) | DRD2DRD3SIGMAR1HTR6 | |
| SCHEMBL2927674 | 0.82 | DRD2 (0.60) | DRD2DRD3SIGMAR1HTR6 | |
| SCHEMBL2925539 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2HTR6POLBMAPK1LMNA | |
| SCHEMBL2929064 | 0.79 | HTR6 (0.53) | SIGMAR1SMN1; SMN2HTR6MAPK1LMNA | |
| SCHEMBL2928049 | 0.78 | DRD2 (0.59) | DRD2DRD3SIGMAR1HTR6 | |
| SCHEMBL310615 | 0.76 | DRD2 (0.60) | DRD2DRD3SIGMAR1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41315-E1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) | 2010-05-04 | — | — | US | disclosed |
| US-6924374-B2 | Central nervous system disorders; psychological disorders | A. CARLSSON RESEARCH AB (SE) | 2005-08-02 | — | — | US | disclosed |
| EP-1419773-A2 | 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004169-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | DRD2 16/4885DRD3 22/4885SIGMAR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.